NxStage will engage System One patients to share their experiences with other end-stage renal disease patients through a series of activities, according to a press release.
“Over the years we have consistently been impressed by the incredible success of patient-to-patient communication and how it continually advocates for and improves access to home hemodialysis therapy. With NxStage Plus One we will facilitate these discussions to help patients choose the best treatment option for their health and lifestyle requirements,” president Joseph Turk said in prepared remark.
Lawrence, Mass.-based NxStage extended its supply deal with Fresenius (NYSE:FMS) til 2016. Fresenius will continue to buy NxStage System One units and related supplies for home hemodialysis therapy in the U.S.